Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product

Long-term Follow-up of Subjects Treated With CAR T Cells

NCT05024175 ·Status: RECRUITING

A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007

NCT05509855 ·Status: ENROLLING_BY_INVITATION

Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies

NCT02473757 ·Status: ENROLLING_BY_INVITATION

Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies

NCT06652633 ·Status: RECRUITING ·Phase: PHASE3

Bio-CAR-T BS Study

NCT05366569 ·Status: RECRUITING

Long-term Follow-up of Study Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product in an Imugene Ltd. Clinical Study

NCT05822427 ·Status: RECRUITING

Long-term Follow-up Study of Patients Receiving CAR-T Cells

NCT03375619 ·Status: RECRUITING

CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

NCT03121625 ·Status: UNKNOWN ·Phase: PHASE1

CAR-T Cells in the Treatment of Malignant Hematological Tumors

NCT05619861 ·Status: UNKNOWN ·Phase: NA

Autologous Hematopoietic Stem Cell Infusion for Prolonged Cytopenia After CAR-T Cell Therapy

NCT07127289 ·Status: RECRUITING ·Phase: PHASE2

CAR T-cell Long-Term Follow-Up, Quality of Life and Adverse Reactions

NCT07048535 ·Status: RECRUITING

The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies

NCT05618041 ·Status: RECRUITING ·Phase: NA

Autologous T Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL) Patients

NCT00058656 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory Acute Myeloid Leukemia

NCT05266950 ·Status: WITHDRAWN ·Phase: PHASE1

CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

NCT03312205 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

CART22 Alone or in Combination With huCART19 for ALL

NCT03620058 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial

NCT06765876 ·Status: RECRUITING ·Phase: EARLY_PHASE1

Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.

NCT05645744 ·Status: TERMINATED

A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...

NCT05621291 ·Status: RECRUITING ·Phase: NA

Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological Tumours

NCT06238336 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL)

NCT02535364 ·Status: TERMINATED ·Phase: PHASE2

Long-term Observational Study of Patients Treated With Inaticabtagene Autoleucel Injection

NCT06461351 ·Status: RECRUITING

Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia

NCT04835519 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Clinical Study of Allogenic CD19-CAR-T in the Treatment of R/R B-Cell Hematologic Malignancies

NCT07316907 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1

Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies

NCT06508775 ·Status: RECRUITING ·Phase: NA